Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

2.

Nicotinamidadenindinucleotide (NADH): the new approach in the therapy of Parkinson's disease.

Birkmayer W, Birkmayer GJ.

Ann Clin Lab Sci. 1989 Jan-Feb;19(1):38-43.

PMID:
2644889
3.

The coenzyme nicotinamide adenine dinucleotide (NADH) improves the disability of parkinsonian patients.

Birkmayer W, Birkmayer GJ, Vrecko K, Mlekusch W, Paletta B, Ott E.

J Neural Transm Park Dis Dement Sect. 1989;1(4):297-302.

PMID:
2597315
4.

Parenteral application of NADH in Parkinson's disease: clinical improvement partially due to stimulation of endogenous levodopa biosynthesis.

Kuhn W, Müller T, Winkel R, Danielczik S, Gerstner A, Häcker R, Mattern C, Przuntek H.

J Neural Transm (Vienna). 1996;103(10):1187-93.

PMID:
9013405
5.
6.

Is NADH effective in the treatment of Parkinson's disease?

Swerdlow RH.

Drugs Aging. 1998 Oct;13(4):263-8. Review.

PMID:
9805207
7.
8.

The clinical benefit of NADH as stimulator of endogenous L-dopa biosynthesis in parkinsonian patients.

Birkmayer W, Birkmayer JG, Vrecko K, Paletta B.

Adv Neurol. 1990;53:545-9. No abstract available.

PMID:
2239495
9.

Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.

Lyytinen J, Kaakkola S, Ahtila S, Tuomainen P, Teräväinen H.

Mov Disord. 1997 Jul;12(4):497-505.

PMID:
9251066
10.

Five-year follow-up of early lisuride and levodopa combination therapy versus levodopa monotherapy in de novo Parkinson's disease. The French Lisuride Study Group.

Allain H, Destée A, Petit H, Patay M, Schück S, Bentué-Ferrer D, Le Cavorzin P.

Eur Neurol. 2000;44(1):22-30.

PMID:
10894991
11.

Strategy and tactic of modern Parkinson therapy.

Birkmayer W, Birkmayer GJ.

Acta Neurol Scand Suppl. 1989;126:63-6. Review.

PMID:
2694735
12.

Treatment of Parkinson's disease: levodopa as the first choice.

Katzenschlager R, Lees AJ.

J Neurol. 2002 Sep;249 Suppl 2:II19-24. Review.

PMID:
12375059
13.

Levodopa and 3-OMD levels in Parkinson patients treated with Duodopa.

Antonini A, Bondiolotti G, Natuzzi F, Bareggi SR.

Eur Neuropsychopharmacol. 2010 Oct;20(10):683-7. doi: 10.1016/j.euroneuro.2010.04.010. Epub 2010 May 31.

PMID:
20570113
15.

Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.

Adamiak U, Kaldonska M, Klodowska-Duda G, Wyska E, Safranow K, Bialecka M, Gawronska-Szklarz B.

Clin Neuropharmacol. 2010 May;33(3):135-41. doi: 10.1097/WNF.0b013e3181d47849.

PMID:
20216409
16.

[The L-dopa test in Parkinson's disease].

Esteguy M, Bonnet AM, Kefalos J, Lhermitte F, Agid Y.

Rev Neurol (Paris). 1985;141(5):413-5. French.

PMID:
4048732
17.

[Effectiveness of slow release L-DOPA/benserazide in treatment of end-of-dose akinesia in Parkinson disease].

Eichhorn TE, Schrag A, Trenkwalder C, Selzer R, Kohnen R, Oertel WH, Poewe W.

Nervenarzt. 1995 Dec;66(12):933-41. German.

PMID:
8584079
18.

Treatment of Alzheimer's disease with stabilized oral nicotinamide adenine dinucleotide: a randomized, double-blind study.

Demarin V, Podobnik SS, Storga-Tomic D, Kay G.

Drugs Exp Clin Res. 2004;30(1):27-33.

PMID:
15134388
19.

Pharmacokinetics and pharmacodynamics of L-Dopa after acute and 6-week tolcapone administration in patients with Parkinson's disease.

Napolitano A, Del Dotto P, Petrozzi L, Dell'Agnello G, Bellini G, Gambaccini G, Bonuccelli U.

Clin Neuropharmacol. 1999 Jan-Feb;22(1):24-9.

PMID:
10047930
20.

Patterns of clinical response and plasma dopa levels in Parkinson's disease.

Tolosa ES, Martin WE, Cohen HP, Jacobson RL.

Neurology. 1975 Feb;25(2):177-83.

PMID:
1167646

Supplemental Content

Support Center